# Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer

> **NCT00616291** · PHASE1 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 14 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine

## Key facts

- **NCT ID:** NCT00616291
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2012-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00616291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00616291, "Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00616291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*